SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CollaGenex (CGPI) FDA PENDING -- Ignore unavailable to you. Want to Upgrade?

To: Tom D who wrote (20)10/22/1997 1:04:00 AM
From: Vector1  Read Replies (1) | Respond to of 142
 
Tom,
The company has asserted that the Tetracycline dose in Periostat is so small it is insufficient to kill bacteria and therefor incapable of inducing the creation of resistant strains. For the reasons you suggest the FDA is looking at this very carefully. No question in mind that CPGI is a 20-25 stock overnight if they recieve approval. Without approval they are virtually worthless. Assuming there is an options market in the stock I think the play here may be to try and get a better sense when a decision will be made and play a straddle.
V1



To: Tom D who wrote (20)4/18/1998 2:20:00 AM
From: thomas larkin  Read Replies (2) | Respond to of 142
 
If a small amount of this anti-biotic is in periostat, then why wouldn't the body build up a resistance for the people who are using large dosages for acne?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News